Intravitreal recombinant human erythropoietin: A safety study in rabbits

Current Eye Research

Volumn 33, Issue 9, 2008, Pages 750-760

  Song, Brian J ^a   Cai, Hui ^a   Tsai, James C ^a,b   Chang, Stanley ^a   Forbes, Max ^a   Del Priore, Lucian V ^a,c  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c New York Presbyterian Hospital   (United States)

Author keywords

Electroretinogram; Erythropoietin; Glaucoma; Intravitreal injection; Retinal degeneration

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG SAFETY; ELECTRORETINOGRAPHY; FLUORESCENCE ANGIOGRAPHY; NEOVASCULARIZATION (PATHOLOGY); NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA INJURY; TREATMENT RESPONSE;

ANIMALS; ELECTRORETINOGRAPHY; ERYTHROPOIETIN, RECOMBINANT; FLUORESCEIN ANGIOGRAPHY; INJECTIONS; RABBITS; RETINA; VITREOUS BODY;

EID: 51949111258     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802366602     Document Type: Article

References (65)

1. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England &Wales. BMC Public Health. 2006;6:58.
2. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713; discussion 829-730.
3. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487-497.
4. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429-440.
5. Anderson DR, Drance SM, Schulzer M. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. Am J Ophthalmol. 2003;136:820-829.
6. Leskea MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: The early manifest glaucoma trial. Curr Opin Ophthalmol. 2004;15:102-106.
7. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev. 1992;72:449-489.
8. Fisher JW. Erythropoietin: Physiology and pharmacology update. Exp Biol Med (Maywood). 2003;228:1-14.
9. Mulcahy L. The erythropoietin receptor. Semin Oncol. 2001;28:19-23.
10. Yoshimura A, Misawa H. Physiology and function of the erythropoietin receptor. Curr Opin Hematol. 1998;5:171-176.
11. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA. 1990;87:5978-5982.
12. Bernaudin M, Marti HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab. 1999;19:643-651.
13. Campana WM, Misasi R, O'Brien JS. Identification of a neurotrophic sequence in erythropoietin. Int J Mol Med. 1998;1:235-241.
14. Yu X, Shacka JJ, Eells JB, et al. Erythropoietin receptor signaling is required for normal brain development. Development. 2002;129:505-516.
15. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.
16. Celik M, Gokmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 2002;99:2258-2263.
17. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA. 2002;99:9450-9455.
18. Agnello D, Bigini P, Villa P, et al. Erythropoietin exerts an antiinflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002;952:128-134.
19. Leist M, Ghezzi P, Giovanni G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004;305:239-242.
20. Gong H, Wang W, Kwon TH, et al. EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int. 2004;66:683-695.
21. Nemoto T, Yokota N, Keane WF, Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int. 2001;59:246-251.
22. Patel NS, Sharples EJ, Cuzzocrea S, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004;66:983-989.
23. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:2115-2124.
24. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW. Erythropoietin protects against ischemic acute renal injury. Nephrol Dial Transplant. 2004;19:348-355.
25. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia reperfusion injury in rat kidney. Faseb J. 2003;17:1754-1755.
26. Grasso G, Meli F, Fodale V, Calapai G, Buemi M, Iacopino DG. Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injury. Laboratory investigation. J Neurosurg Spine. 2007;7:645-651.
27. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100:4802-4806.
28. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003;100:11612-11617.
29. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007.
30. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: A potential role for cardiac fibroblasts. J Biol Chem. 2004;279:20655-20662.
31. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med. 2002;8:718-724.
32. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci. 2007;48:1212-1218.
33. Rex TS, Allocca M, Domenici L, et al. Systemic but not intraocular EPO gene transfer protects the retina from light- and genetic-induced degeneration. Mol Ther. 2004;10:855-861.
34. Grimm C, Wenzel A, Stanescu D, et al. Constitutive overexpression of human erythropoietin protects the mouse retina against induced but not inherited retinal degeneration. J Neurosci. 2004;24:5651-5658.
35. Fu QL, Wu W, Wang H, Li X, Lee VW, So KF. Up-regulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension. Cell Mol Neurobiol. 2008;28:317-329.
36. Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008;49:732-742.
37. Zhu B, Wang W, Gu Q, Xu X. Erythropoietin protects retinal neurons and glial cells in early-stage streptozotocin-induced diabetic rats. Exp Eye Res. 2008;86:375-382.
38. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2002;99:10659-10664.
39. Ranchon Cole I, Bonhomme B, Doly M. Pre-treatment of adult rats with high doses of erythropoietin induces caspase-9 but prevents light-induced retinal injury. Exp Eye Res. 2007;85:782-789.
40. Weishaupt JH, Rohde G, Polking E, Siren AL, Ehrenreich H, Bahr M. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 2004;45:1514-1522.
41. Kilic U, Kilic E, Soliz J, Bassetti CI, Gassmann M, Hermann DM. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. Faseb J. 2005;19:249-251.
42. King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, Beazley LD. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol. 2007;205:48-55.
43. Tsai JC, Wu L, Worgul B, Forbes M, Cao J. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr Eye Res. 2005;30:1025-1031.
44. Hwang D, Tari S, Wu L, Chang S, Forbes M, Tsai JC. Retinal function assessment following intravitreal injection of erythropoietin in rats: A dose-toxicity study. Invest Ophthalmol Vis Sci. 2006;47:E-Abstract 5724.
45. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens. 1990;3:947-955.
46. Dai C, Chung IJ, Krantz SB. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. Exp Hematol. 2005;33:152-158.
47. Wong CG, Rich KA, Liaw LH, Hsu HT, Berns MW. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr Eye Res. 2001;22:140-147.
48. Wachtmeister L. Oscillatory potentials in the retina: What do they reveal. Prog Retin Eye Res. 1998;17:485-521.
49. Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci. 2004;22:105-119.
50. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-792.
51. Hardee ME, Cao Y, Fu P, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE. 2007;2:e549.
52. Takagi H, Watanabe D, Suzuma K, et al. Novel role of erythropoietin in proliferative diabetic retinopathy. Diab Res Clin Pract. 2007 Sep;77(S1):S62-64.
53. Ribatti D, Poliani PL, Longo V, Mangieri D, Nico B, Vacca A. Erythropoietin/ erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology. 2007;50:636-641.
54. Sayan H, Ozacmak VH, Guven A, Aktas RG, Ozacmak ID. Erythropoietin stimulates wound healing and angiogenesis in mice. J Invest Surg. 2006;19:163-173.
55. Hardee ME, Kirkpatrick JP, Shan S, et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer. 2005;93:1350-1355.
56. Hale SA, Wong C, Lounsbury KM. Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells. Gynecol Oncol. 2006;100:14-19.
57. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118:526-533.
58. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA. 2004;101:14907-14912.
59. Grover S, Fishman GA, Birch DG, Locke KG, Rosner B. Variability of full-field electroretinogram responses in subjects without diffuse photoreceptor cell disease. Ophthalmology. 2003;110:1159-1163.
60. Jacobi PC, Miliczek KD, Zrenner E. Experiences with the international standard for clinical electroretinography: Normative values for clinical practice, interindividual, and intraindividual variations and possible extensions. Doc Ophthalmol. 1993;85:95-114.
61. Birch DG, Hood DC, Locke KG, Hoffman DR, Tzekov RT. Quantitative electroretinogram measures of phototransduction in cone and rod photoreceptors: Normal aging, progression with disease, and testretest variability. Arch Ophthalmol. 2002;120:1045-1051.
62. Fishman GA, Chappelow AV, Anderson RJ, Rotenstreich Y, Derlacki DJ. Short-term inter-visit variability of erg amplitudes in normal subjects and patients with retinitis pigmentosa. Retina. 2005;25:1014-1021.
63. Aydin E, Kazi AA, Peyman GA, Esfahani MR. Intravitreal toxicity of moxifloxacin. Retina. 2006;26:187-190.
64. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257-261.
65. Gitter S, Pardo A, Kariv N, Yinon U. Enhanced electroretinogram in cats induced by exposure to mercury acetate. Toxicology. 1988;51:67-76.